Hologic's second quarter revenue decreased by 7.6% due to the Cynosure divestiture, but organic revenue increased by 0.5%. The company reported GAAP diluted EPS of $0.36 and non-GAAP diluted EPS of $0.57. Hologic is also introducing a second high-throughput Coronavirus test for its Panther® platform.
Second quarter revenue decreased 7.6% due to Cynosure divestiture, 7.1% in constant currency.
Organic revenue increased 0.5%, 1.1% in constant currency.
Company posted GAAP diluted EPS of $0.36, non-GAAP diluted EPS of $0.57.
Company to introduce second high-throughput Coronavirus test for Panther® Platform.
Hologic expects the COVID-19 pandemic to have a significant negative impact on its future revenue and operating income, especially in the third quarter of fiscal 2020 and withdrew its financial guidance for the second quarter and full year 2020.
Visualization of income flow from segment revenue to net income